(d)

	Proteinuria (after conversion unless otherwise stated), % recipients
Sirolimus studies
Early conversion (≤3 months after transplantation)
Harper et al.  Transplantation. 2011; 91: 128–32 [67]	Proteinuria: preconversion: 45; 6 months: 72; 3 years: 63; 5 years: 58
Late conversion (>3 months after transplantation)
DuBay et al.  Liver Transpl. 2008; 14: 651–9 [72]	7 versus 4 (SRL versus CNI)
Herlenius et al.  Transplant Proc. 2010; 42: 4441–8 [73]	8.3 versus 7.7 (SRL versus MMF)
Morard et al.  Liver Transpl. 2007; 13: 658–64 [75]	Albuminuria: 36
Uhlmann et al.  ExpClin Transplant. 2012; 10: 30–8 [77]	Proteinuria increased at 6 months after conversion (P < 0.05)
Wadei et al. Transplantation. 2012; 93: 1006–12 [86]	81
Everolimus studies
Early conversion (≤3 months after transplantation)
De Simone et al.  Am J Transplant. 2012; 12: 3008–20 [87]	EVR + TAC-RD versus TAC-SD: 2.9 versus 0.4 (RR: 6.89, 95% CI 0.85, 55.54)
Fischer et al.  Am J Transplant. 2012; 12: 1855–65 [50]	EVR versus CNI: 9.9 versus 2.0
Late conversion (>3 months after transplantation)
Castroagudín et al. Liver Transpl. 2009; 15: 1792–7 [94]	38.1
Saliba et al. Liver Transpl. 2011; 17: 905–13 [98]	5.4
Vallin et al.  Clin Transplant. 2011; 25: 660–9 [99]	13 versus 29 (pre- versus after conversion, P < 0.05)

P values are included where available.

CNI: calcineurin inhibitor; EVR: everolimus; MMF: mycophenolate mofetil; SRL: sirolimus; RR: relative risk; 95% CI: 95% confidence interval; TAC: tacrolimus; TAC-RD: reduced-dose tacrolimus (C0: 3–5 ng/mL); TAC-SD: standard-dose tacrolimus (C0: 6–10 ng/mL).